期刊文献+

新型胰高血糖素样肽-1(GLP-1)受体激动剂的固相合成及其生物活性研究 被引量:1

Solid Phase Synthesis and Biological Activity Studies of Novel GLP-1 Receptor Agonists
下载PDF
导出
摘要 目的寻找高效、长效的新型GLP-1受体激动剂。方法非洲爪蟾GLP-1(XenGLP-1)的半衰期较短,设计三个半胱氨酸改构的XenGLP-1类似物,优选高降糖活性的多肽进一步PEG化修饰。结果 PEG-XenGLP-1缀合肽具有优异的长效降糖活性。结论从动物源寻找新型GLP-1类药物是降糖药物研究的新思路。对GLP-1类多肽进行PEG化修饰,可在降糖活性保持的前提下显著延长多肽的半衰期。 OBJECTIVE To search novel GLP-1 receptor agonists based on animal GLP-1 sequence,and represents a facile and useful method for developing novel GLP-1 analogs.METHODS The biological activities of XenGLP-1 is limited by its short half-lives.In this study,Cysteine was first introduced to XenGLP-1 and three XenGLP-1 analogs were synthesized,and the selected peptides were further PEGlyated to improve the half-life.RESULTS The glucose-lowering and long-term hypoglycemic activities of PEGlyated XenGLP-1 conjugates were improved.CONCLUSION Searching novel GLP-1 receptor agonists based on animal GLP-1 sequence represents a facile and useful method for developing novel GLP-1 analogs.Peptide chemical conjugated with PEG would not influence the hypoglycemic activity and could improve the long-term glucose-lowering activity.
出处 《海峡药学》 2017年第12期51-55,共5页 Strait Pharmaceutical Journal
基金 国家自然科学基金青年项目(81602964) 江苏高校品牌专业建设工程项目(专业序号PPZY2015B110)
关键词 GLP-1泪相合成 PEG化 GLP-1 solid phase synthesis PEGylated
  • 相关文献

参考文献1

二级参考文献28

  • 1马义,周天鸿.胰高血糖素样肽1的研究及应用进展[J].中国组织工程研究与临床康复,2007,11(29):5806-5809. 被引量:10
  • 2Nakagawa A, Satake H, Nakabayashi H, et al. Receptor gene expression of glucagons like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglin cells[ J ]. Auton Neurosci,2004,110( 1 ) :36 -43.
  • 3Bulotta A, Hui H, Anastasi e, et al. Cultured pancreatic ductal cells undergo cell cycle re-distribution and beta-cell like differentiation in response to glucogan-like peptide-1 [ J]. J Mol Endocrion1,2002,29 ( 3 ) :347 - 360.
  • 4Wang YP, Liu LB. Protection of glucagon-like peptide-1 on pancreatic fl-cell [ J ] . Int J Endocrinol Metab, 2007,27 ( 2 ) : 98 - 100.
  • 5Chee WC, Josephine ME. Biology and therapeutic potential of GLP-1 in the treatment of diabetes [ J ]. Drug Discov Today Dis Mech ,2005,2 ( 3 ) :295 - 301.
  • 6Ahren B, Olsson ML, Jansson PA, et al. Inhibition of dipeptidyl peptidase-r reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes [ J ]. J Clin Endocrinol Metab , 2004,89(5) :2 078 -2 084.
  • 7Little TJ, Pilichiewicz AN, Russo A, et al. Effects of Intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects:relationships with postprandial glycemic and insulinemic responses [ J ]. J Clln Endocrinol Metab ,2006,91(5) :1 916-1 923.
  • 8Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes[ J]. Lancet,2006,368 ( 1 ! ) : 1 696 - 1 705.
  • 9Gotthardt M, Lalyko G, van Eerd-Vismale J, et al. A new technique for in vivo imaging of specific GLP-1 binding sites : First results in small rodents [ J ]. Regul Pept,2006,137 ( 3 ) : 162 - 167.
  • 10Hagemann D, Holst JJ,Gethmann A,et al. Glucagon-like peptide 1 (GLP-1)suppresses ghrelin levels in humans via increased insulin secretion [ J ]. Regul Pept ,2007 ,143 ( 1-3 ) : 64 - 68.

共引文献27

同被引文献4

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部